Abstract Number: 1688 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…Abstract Number: 1689 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Background/Purpose: PsA has a negative impact on patients’ quality of life, physical function, and work productivity. Ixekizumab (IXE) is an IgG4 mAb that binds with…Abstract Number: 1690 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results
Background/Purpose: Psoriasis is a chronic systemic inflammatory disease often treated with conventional systemic and biologic drugs that may variously be ineffective, be inaccessible, or pose…Abstract Number: 1691 • 2016 ACR/ARHP Annual Meeting
The Comparative Immunogenicity of Biologic Therapy and Its Clinical Relevance in Psoriatic Arthritis: A Systematic Review of the Literature
Background/Purpose: Anti-inflammatory biologic agents have been shown to provide significant benefit in controlling disease activity in psoriatic arthritis (PsA) and inhibiting progression of joint damage.…Abstract Number: 1692 • 2016 ACR/ARHP Annual Meeting
Validation of a Two-Question Patient Reported Outcome Measure for Psoriasis
Background/Purpose: While the psoriasis area and severity index (PASI) is the most commonly used assessment tool for psoriasis severity, it has been criticized for its…Abstract Number: 1693 • 2016 ACR/ARHP Annual Meeting
Chronic Back Pain in Early Psoriatic Arthritis
Background/Purpose: Axial involvement is less well studied in peripheral spondyloarthritis where chronic back pain is not the predominant symptom, such as in psoriatic arthritis (PsA).…Abstract Number: 1694 • 2016 ACR/ARHP Annual Meeting
Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?
Background/Purpose: The Tight Control of PsA (TICOPA) study was the first to address treat to target in PsA using the minimal disease activity (MDA)…Abstract Number: 1695 • 2016 ACR/ARHP Annual Meeting
Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Background/Purpose: Up to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of…Abstract Number: 1696 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab
Background/Purpose: Minimal disease activity (MDA) is an important goal for patients with rheumatologic disorders, including psoriatic arthritis (PsA). The assessment of MDA could potentially help…Abstract Number: 1697 • 2016 ACR/ARHP Annual Meeting
Validity of Diagnostic Codes and Point Prevalence of Psoriatic Arthritis in Israel – a Population-Based Study
Background/Purpose: The information on the population-based prevalence of Psoriatic Arthritis (PsA) is limited. Large population-based databases provide an opportunity to study the epidemiology of PsA,…Abstract Number: 1698 • 2016 ACR/ARHP Annual Meeting
Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis
Background/Purpose: Psoriatic arthritis (PsA) often develops between the 3rd to 5th decades of life. However, little is known about PsA activity and prognosis among patients…Abstract Number: 1699 • 2016 ACR/ARHP Annual Meeting
RAPID3 Near Remission Shows Good Agreement with Minimal Disease Activity Criteria in Psoriatic Arthritis
Background/Purpose: RAPID3 (routine assessment of patient index data) is a patient self-report index which is feasible in busy clinical settings to assess severity and change…Abstract Number: 1700 • 2016 ACR/ARHP Annual Meeting
Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa
Background/Purpose: PASDAS is a composite disease activity measure (range 0–10) for psoriatic arthritis (PsA). Recently, PASDAS disease activity cutoffs were proposed and a minimal disease…Abstract Number: 1701 • 2016 ACR/ARHP Annual Meeting
The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis
Background/Purpose: Depression and anxiety are well known comorbidities in psoriasis (PsO) and psoriatic arthritis (PsA) with higher prevalence in PsA. Patients with PsA have…Abstract Number: 1702 • 2016 ACR/ARHP Annual Meeting
Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: The objective of this analysis was to investigate differences in baseline demographic and clinical characteristics of patients with psoriatic arthritis (PsA) who responded to…
ACR Meeting Abstracts